Bausch Health (BHC) Lags Q2 Earnings Estimates

Core Viewpoint - Bausch Health (BHC) reported quarterly earnings of $0.9 per share, missing the Zacks Consensus Estimate of $0.97 per share, representing an earnings surprise of -7.22% [1]. Financial Performance - The company posted revenues of $2.53 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.42%, compared to year-ago revenues of $2.4 billion [2]. - Over the last four quarters, Bausch has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2]. Stock Performance - Bausch shares have lost about 15.4% since the beginning of the year, while the S&P 500 has gained 8.3% [3]. - The current consensus EPS estimate for the coming quarter is $1.13 on $2.57 billion in revenues, and for the current fiscal year, it is $3.96 on $10 billion in revenues [7]. Industry Outlook - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8]. - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Bausch's stock performance [5]. Future Expectations - The estimate revisions trend for Bausch was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6]. - The upcoming earnings call will be crucial for understanding management's commentary on future earnings expectations [3].